TY - JOUR
T1 - Gut microbiota
T2 - A potential new territory for drug targeting
AU - Jia, Wei
AU - Li, Houkai
AU - Zhao, Liping
AU - Nicholson, Jeremy K.
N1 - Funding Information:
This work was financially supported by the National Basic Research Program of China (2007CB914700) and the International Collaborative Project, Chinese Ministry of Science and Technology (2006DFA02700).
PY - 2008/2
Y1 - 2008/2
N2 - The significant involvement of the gut microbiota in human health and disease suggests that manipulation of commensal microbial composition through combinations of antibiotics, probiotics and prebiotics could be a novel therapeutic approach. A systems perspective is needed to help understand the complex host-bacteria interactions and their association with pathophysiological phenotypes so that alterations in the composition of the gut microbiota in disease states can be reversed. In this article, we describe the therapeutic rationale and potential for targeting the gut microbiota, and discuss strategies and systems-oriented technologies for achieving this goal.
AB - The significant involvement of the gut microbiota in human health and disease suggests that manipulation of commensal microbial composition through combinations of antibiotics, probiotics and prebiotics could be a novel therapeutic approach. A systems perspective is needed to help understand the complex host-bacteria interactions and their association with pathophysiological phenotypes so that alterations in the composition of the gut microbiota in disease states can be reversed. In this article, we describe the therapeutic rationale and potential for targeting the gut microbiota, and discuss strategies and systems-oriented technologies for achieving this goal.
UR - http://www.scopus.com/inward/record.url?scp=38849190556&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=38849190556&partnerID=8YFLogxK
U2 - 10.1038/nrd2505
DO - 10.1038/nrd2505
M3 - Article
C2 - 18239669
AN - SCOPUS:38849190556
SN - 1474-1776
VL - 7
SP - 123
EP - 129
JO - Nature Reviews Drug Discovery
JF - Nature Reviews Drug Discovery
IS - 2
ER -